Evolus, Inc. (EOLS) vs Puma Biotechnology, Inc. (PBYI)
A side-by-side comparison of Evolus, Inc. and Puma Biotechnology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EOLS
Evolus, Inc.
$7.55HealthcareDelayed quote: Oct 6, 2026, 12:20 PM EDT
PBYI
Puma Biotechnology, Inc.
$9.58HealthcareDelayed quote: Oct 6, 2026, 12:14 PM EDT
Total return — EOLS vs PBYI
growth of $100 · dividends reinvested · last 9yEOLS -35.0% (-4.7%/yr)PBYI -84.8% (-18.9%/yr)EOLS compounded faster over this window
EOLS PBYI
EOLS vs PBYI: by the numbers
- •EOLS is the larger company ($497M vs $487M market cap).
- •PBYI is profitable (11.55% net margin) while EOLS runs a net loss (-10.85%).
- •EOLS grew revenue faster over the past five years (32.82% vs 0.29% CAGR).
Metrics side by side
Valuation
| Metric | EOLS | PBYI |
|---|---|---|
| P/E ratio | N/A | 18.55 |
| Forward P/E | N/A | 25.20 |
| P/S ratio | 1.57 | 2.11 |
| P/B ratio | N/A | 3.52 |
| EV / EBITDA | N/A | 10.50 |
| FCF yield | N/A | 8.43% |
Profitability
| Metric | EOLS | PBYI |
|---|---|---|
| Gross margin | 66.25% | 74.83% |
| Operating margin | -7.33% | 13.16% |
| Net margin | -10.85% | 11.55% |
| ROE | N/A | 19.28% |
| ROIC | -15.54% | 18.26% |
Growth (annualized)
| Metric | EOLS | PBYI |
|---|---|---|
| Revenue CAGR (5Y) | 32.82% | 0.29% |
| FCF CAGR (5Y) | N/A | 90.51% |
| Total return CAGR (5Y) | 0.46% | 9.26% |
Frequently asked
- Which has grown faster, EOLS or PBYI?
- Over the past five years, EOLS grew revenue faster — EOLS at a 32.82% CAGR versus PBYI at 0.29%.
- Is EOLS or PBYI more profitable?
- PBYI runs the higher net margin — EOLS at -10.85% versus PBYI at 11.55%.
- How have EOLS and PBYI total returns compared?
- Over the past 5 years, EOLS delivered 0.46% and PBYI delivered 9.26% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Puma Biotechnology P/E ratioEvolus ROEPuma Biotechnology ROEEvolus operating marginPuma Biotechnology operating marginEvolus revenue growthPuma Biotechnology revenue growthEvolus free cash flowPuma Biotechnology free cash flow
Evolus & Puma Biotechnology appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.